C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b.
Schmidt
Stephan
S
Schneider
Tobias
T
Schmidt-Wolf
Ingo
I
Ko
Yon
Y
Schlegel
Uwe
U
Klockgether
Thomas
T
Hertfelder
Hans-Jörg
HJ
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000368:Aged; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010265:Paraproteinemias / Q000097:blood / Q000150:complications*; D015843:Serpins / Q000097:blood* / Q000172:deficiency
D000276:Adjuvants, Immunologic; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; C469952:SERPING1 protein, human; D015843:Serpins; D000068576:Interferon beta-1b; D016899:Interferon-beta